InsiderTrades.com logo
This is the worst sign for the U.S. stock market in 50 years
From Stansberry Research   |   Ad
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Click here to see Dan's new, urgent warning about the U.S. market for 2025.
Romulus K. Brazzell net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Romulus Brazzell Biography and Net Worth

Insider of KALA BIO
Dr. Brazzell has served as our Chief Medical Officer since February 2013. He has also served as a Principal of Acuity Advisors, LLC, an ophthalmic consulting company, from January 2014 to July 2018. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2012 until December 2015. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focusing on ophthalmic products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalmology Business from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Kentucky.

How do I contact Romulus K. Brazzell?

The corporate mailing address for Dr. Brazzell and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at [email protected]. Learn More on Romulus K. Brazzell's contact information.

Has Romulus K. Brazzell been buying or selling shares of KALA BIO?

Romulus K. Brazzell has not been actively trading shares of KALA BIO during the last quarter. Most recently, Romulus K. Brazzell sold 3,504 shares of the business's stock in a transaction on Tuesday, January 4th. The shares were sold at an average price of $1.30, for a transaction totalling $4,555.20. Learn More on Romulus K. Brazzell's trading history.

Who are KALA BIO's active insiders?

KALA BIO's insider roster includes Todd Bazemore (COO), Romulus Brazzell (Insider), Hongming Chen (Insider), Mark Iwicki (CEO), and Mary Reumuth (CFO). Learn More on KALA BIO's active insiders.

Are insiders buying or selling shares of KALA BIO?

In the last twelve months, insiders at the sold shares 8 times. They sold a total of 41,021 shares worth more than $221,381.84. The most recent insider tranaction occured on June, 26th when insider Todd Bazemore sold 4,653 shares worth more than $22,101.75. Insiders at KALA BIO own 8.3% of the company. Learn More about insider trades at KALA BIO.

Information on this page was last updated on 6/26/2024.

Romulus K. Brazzell Insider Trading History at KALA BIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2022Sell3,504$1.30$4,555.20View SEC Filing Icon  
See Full Table

Romulus K. Brazzell Buying and Selling Activity at KALA BIO

This chart shows Romulus K Brazzell's buying and selling at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KALA BIO Company Overview

KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $5.92
Low: $5.75
High: $6.04

50 Day Range

MA: $6.44
Low: $5.11
High: $7.63

2 Week Range

Now: $5.92
Low: $4.21
High: $9.25

Volume

12,938 shs

Average Volume

78,538 shs

Market Capitalization

$27.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
This is the worst sign for the U.S. stock market in 50 years
From Stansberry Research   |   Ad
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Click here to see Dan's new, urgent warning about the U.S. market for 2025.